Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tylamac phase II study in onchocerciasis
PACTR202104600961505Phase 2Unknown
- Sponsor
- Drugs for Neglected
- Start
- Apr 2021
- Modality
- Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of Flubentylosin, albendazole and ivermectin in onchocerciasis (9 arms), sponsored by Drugs for Neglected. Status: unknown.
02
Drugs
Flubentylosinalbendazoleivermectin
03
Conditions
onchocerciasis
Beyond the preview
Go deeper on PACTR202104600961505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202104600961505.